EUDA

Euda Health Holdings Limited - Ordinary Shares$14.76

NASDAQStockneutral 14%

Price Chart

Overlays

126 data points+1.00 over periodRSI(14): 27.9

Quant Score History

0 weakest · 5 strongest

Sell1.54 / 5Price-based: momentum, trend, volatility, drawdown.How this is calculated →

Technical Indicators

RSI (14)

27.9

Dividends & Splits

Ex-Dividend

No dividend history.

Split

2026-03-231:20

Split-Adjusted Basis

341 of 500 bars in this window predate a split, so they are restated on the latest share basis (cumulative factor up to ×20.0000). The chart above plots raw closes.

close = rawClose × adjFactor, so any move spanning the split is measured on one share basis.

Company Overview

Statement fields are the latest reported fiscal year (FY2025 FY), not a rolling TTM.

Market Cap

548.38M

P/E

-9.97

Fwd P/E

9.22

P/B

-214.79

P/S

80.40

EV/Rev

80.40

Div Yield

—

Div/Share

—

Revenue (FY)

6.82M

Net Income (FY)

-2.77M

EPS (FY)

-1.48

Profit Margin

-40.65%

ROE

108.61%

ROA

-130.64%

52W High

71.20

52W Low

5.26

50D MA

15.78

200D MA

15.07

Shares Out

37.15M

Analyst Target

55.00

Factor Grades

Hold

Value

C+

Growth

B+

Profit.

C+

Momentum

EPS Rev.

Quant Score: 2.8 / 5

Model score computed from reported data. Not a recommendation.

Risk & Return

Ann. Return

9.63%

Volatility

142.76%

Sharpe

0.06

Beta

—

Alpha

—

Max Drawdown

95.65%

VaR (95%)

10.63%

Sortino

0.11

Upcoming Earnings

No scheduled earnings date.

News

YYahoo Finance

EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore

Opens in a new tab ↗

YYahoo Finance

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

Opens in a new tab ↗

YYahoo Finance

EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

Opens in a new tab ↗

YYahoo Finance

EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

Opens in a new tab ↗

YYahoo Finance

EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

Opens in a new tab ↗

YYahoo Finance

EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

Opens in a new tab ↗

YYahoo Finance

EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities

Opens in a new tab ↗

YYahoo Finance

EUDA Health price target lowered to $2.75 from $6 at Greenridge

Opens in a new tab ↗